Pharmacogenomics Studies of Antidepressants

National Cheng-Kung University Hospital1 site in 1 country200 target enrollmentMarch 2007

ConditionsMajor Depressive Disorder Antidepressive Agents Pharmacogenetics Venlafaxine Fluoxetine

InterventionsVenlafaxine Fluoxetine

DrugsVenlafaxine Fluoxetine

Overview

Phase: Phase 4
Intervention: Venlafaxine
Conditions: Major Depressive Disorder
Sponsor: National Cheng-Kung University Hospital
Enrollment: 200
Locations: 1
Primary Endpoint: Hamilton Depression Rating Scale (HDRS)
Last Updated: 15 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to establish the clinical effectiveness of antidepressants by pharmacogenomic approach, and to determine the levels of inflammatory factors between the baseline and the end point of the study in Taiwanese major depressive disorder (MDD) patients.

Registry

clinicaltrials.gov

Start Date

March 2007

End Date

February 2011

Last Updated

15 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

National Cheng-Kung University Hospital

Eligibility Criteria

Inclusion Criteria

•Age: 16-65 years old
•Signed informed consent by patient or legal representative
•Hamilton Rating Scale for Depression (HDRS) scores ≥ 16
•A diagnosis of MDD according to DSM-IV criteria made by a specialist in psychiatry

Exclusion Criteria

•monoamine oxidase inhibitor or antidepressant treatment within two weeks prior to entering the study
•A DSM-IV diagnosis of substance abuse within the past three months
•An organic mental disease, mental retardation or dementia
•A serious surgical condition or physical illness
•Patients who were pregnant or breastfeeding